Clinical Oncology
Current issue
Most read in this issue
- Treatment of Erdheim-Chester disease from the perspective in 2026
- Strategies for utilizing Ki67 and multigene assays as a window of opportunity in the treatment of HR+/HER2– early breast cancer in clinical practice
- Dlouhá cesta k RAS (on) inhibitoru
- IgG4-related disease – treatment with anti-CD20, anti-CD19 antibodies, and other new drugs
Journal archive
2026
2025
2024
2023
2022
2021
2020
Issue 6
Issue Supplementum 3
Issue Supplementum - 2
Issue Suppl 1
Issue 4
Issue 5
Issue 3
Issue 2
Issue 1
2019
Issue 6
Issue Supplementum 3
Issue 5
Issue 4
Issue Supplementum2
Issue 3
Issue 2
Issue Supplementum1
Issue 1
2018
2017
Issue 6
Issue Supplementum3
Issue Online only
Issue 5
Issue 4
Issue Supplementum2
Issue 3
Issue Supplementum1
Issue 2
Issue 1
2016
Issue 6
Issue 5
Issue Supplementum 4
Issue Supplementum 3
Issue 4
Issue 3
Issue 2
Issue 1
Issue Supplementum 1
- Hodnocení klinického stadia a léčebné odpovědi u maligních lymfomů – doporučení Kooperativní lymfomové skupiny na základě revidovaných kritérií z roku 2014 (Luganská klasifikace)
- SBORNÍK ABSTRAKT XL. brněnské onkologické dny a XXX. konference pro nelékařské zdravotnické pracovníky 27.–29. 4. 2016, Brno
2015
Issue 6
Issue Supplementum 4
Issue Supplementum 3
Issue 5
Issue 4
Issue Supplementum 2
Issue 3
Issue Supplementum 1
Issue 2
Issue 1
2014
2013
2012
2011
2010
2009
About the journal
- Evaluation of the m7-FLIPI score in patients with follicular lymphoma revealed a promising predictive biomarker for determining suitable chemotherapy
- Kadcyla in a New Indication – Adjuvant Therapy for Early HER2+ Breast Cancer
- Polatuzumab Vedotin in Combination Treatment of Patients with R/R DLBCL
- Prognostic Significance of Lymphopenia for Stratification of Patients with Follicular Lymphoma